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Abstract
Background: The findings of prospective cohort studies are inconsistent regarding the association between dietary
magnesium intake and serum magnesium concentration and the risk of hypertension. We aimed to review the
evidence from prospective cohort studies and perform a dose-response meta-analysis to investigate the relationship
between dietary magnesium intake and serum magnesium concentrations and the risk of hypertension.
Methods: We searched systematically PubMed, EMBASE and the Cochrane Library databases from October 1951
through June 2016. Prospective cohort studies reporting effect estimates with 95% confidence intervals (CIs) for
hypertension in more than two categories of dietary magnesium intake and/or serum magnesium concentrations
were included. Random-effects models were used to combine the estimated effects.
Results: Nine articles (six on dietary magnesium intake, two on serum magnesium concentration and one on both)
of ten cohort studies, including 20,119 cases of hypertension and 180,566 participates, were eligible for inclusion in
the meta-analysis. We found an inverse association between dietary magnesium intake and the risk of hypertension
[relative risk (RR) = 0.92; 95% CI: 0.86, 0.98] comparing the highest intake group with the lowest. A 100 mg/day
increment in magnesium intake was associated with a 5% reduction in the risk of hypertension (RR = 0.95; 95%
CI: 0.90, 1.00). The association of serum magnesium concentration with the risk of hypertension was marginally
significant (RR = 0.91; 95% CI: 0.80, 1.02).
Conclusions: Current evidence supports the inverse dose-response relationship between dietary magnesium intake
and the risk of hypertension. However, the evidence about the relationship between serum magnesium
concentration and hypertension is limited.
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Background
Cardiovascular diseases (CVD), stroke, and renal failure
are the major causes of death with hypertension being
the predominant risk factor [1]. The prevalence of
hypertension has increased rapidly, with an estimated in-
cidence of 29.6% among the U.S. adults [2]. Of the risk
factors that increase mortality, high blood pressure is
the leading factor in women and the second-leading fac-
tor in men [3]. The increasing incidence of hypertension
has raised concerns on the potential risk factors of
hypertension around the world [4]. Causes of hyperten-
sion include, but are not limited to, smoking, sedentary
lifestyle, a diet rich in sodium, and an inadequate dietary
intake of other mineral nutrients, such as, potassium,
calcium and magnesium [5, 6].
Magnesium, the fourth most abundant mineral nutrient
in human body, plays an essential role in regulating blood
pressure, insulin metabolism, cardiac excitability and ad-
enosine triphosphate (ATP) metabolism. However,the
daily magnesium intake in western countries has been de-
clining from approximately 500 mg/day to nearly 175–
225 mg/day since the beginning of the last century, result-
ing in the increased likelihood of magnesium deficiencies
among the western population [7]. However, the associ-
ation between magnesium and blood pressure remained
inconclusive, with the inverse association having been
found in some studies [8–13], but not in others [14–16].
The effect of magnesium supplementation on blood pres-
sure has been investigated in clinical trial since the 1980s
[17]. Several studies support the role of magnesium defi-
ciency caused by lack of dietary and/or supplementary
magnesium intake in the development of hypertension
[18–20]. Nevertheless, to date four meta-analyses have
been conducted but reported inconsistent findings on the
relationship between magnesium supplementation and
blood pressure [21–24]. Also, the association between
dietary magnesium intake and serum magnesium concen-
tration and the risk of hypertension, studies have yielded
inconsistent findings [25–33]. A negative association was
demonstrated in two studies [25, 30], while others did not
find any association [26–29, 31–33].
To our knowledge, the association between dietary
magnesium intake and/or serum magnesium concentra-
tion and the risk of hypertension focusing prospectively
collected data have not been summarized. Thus we con-
ducted a dose-response meta-analysis to quantitatively
elucidate the association between dietary magnesium in-
take and serum magnesium concentration and the risk
of hypertension.
Methods
Data sources and search strategy
We conducted a systematic review for the prospective
cohort studies that evaluated the association of dietary
magnesium intake and/or serum magnesium concentra-
tion with the risk of hypertension. Retrospective cohort
studies or historical cohort studies were not included be-
cause in such study design information of confounding
factors were not always sufficiently available as the data
were not collected for studying magnesium and blood
pressure. We followed the standard criteria PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-Analysis) and MOOSE (Meta-analysis of Observa-
tional Studies in Epidemiology) [34, 35]. The review was
registered in the PROSPERO-international prospective
register of systematic reviews (http://www.crd.york.a-
c.uk/prospero/, registration number: CRD42016039061).
Prospective cohort studies published before June 2016
examining the relationship between dietary magnesium
intake and/or serum magnesium concentration and the
risk of hypertension were included in our study, regard-
less of language and publication status (published, in
press or in progress). Two authors (HH and XW) inde-
pendently searched PubMed, EMBASE, and the
Cochrane Library electronic databases for articles using
the following keywords: magnesium, Mg, hypertension,
high blood pressure, combined with cohort, nested case-
control or prospective. Furthermore, we manually
searched potential articles in the references cited in rele-
vant original and review articles.
Selection criteria
Only studies that met the inclusion criteria were in-
cluded in the meta-analysis: 1) the use of a prospective
study design (cohort or nested case-control study); 2)
dietary magnesium intake and/or serum magnesium
concentration classified into three categories or more; 3)
the outcome being the incident hypertension; 4) the use
of adult population (age > 18 years); 5) the relative risk
(RR), odds ratio (OR) or hazard ratio(HR)with corre-
sponding 95% confidence interval (CI) being reported.
We excluded cross-sectional studies because it may be
difficult to ascertain the temporal association.
Data extraction and quality assessment
Data extraction and quality assessment were conducted
independently by two reviews (HH and XF). The follow-
ing data were extracted from each eligible study: first au-
thor’s surname, year of publication, study country, study
design, population, duration of follow-up, sample size
(number of hypertension cases and total number of par-
ticipants), sex, age, recruitment time, measure and range
of exposure, outcome assessment, effect size (OR, RR or
HR), 95% CIs and covariates adjusted in statistical ana-
lysis. For studies that reported several multivariable-
adjusted effect estimates, we selected the one that was
adjusted for all available potential confounding variables.
Quality assessment for studies was conducted using the
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9-star New-castle-Ottawa Scale (NOS) [36]. Studies with
an NOS score of ≥ 7 were considered high-quality.
Statistical analysis
RRs were used as the common measure of association and
HRs and ORs were transformed into RRs [37, 38]. If a study
reported results involving different populations (male and
female) but did not report the overall results, the results for
each population were regarded as a different study [39];
likewise, a study that reported both dietary magnesium in-
take and serum magnesium concentration was regarded as
two separated studies. The statistical heterogeneity among
the studies was assessed using I2 statistics [40].
A fixed-effect model was used to estimate the pooled
RR when there was no evidence of heterogeneity; other-
wise, a random-effect model was conducted [41]. Forest
plots were produced to assess the RR estimates and cor-
responding 95% CI. Firstly, we pooled the risk estimates
for the highest does/concentration categories of dietary/
serum magnesium compared with the lowest categories.
We subsequently transformed category-specific risk esti-
mates into RRs associated with every 100 mg/day incre-
ment in dietary magnesium intake via the generalized
least squares for trend estimation. Meanwhile, we also
performed a two-stage random-effect dose-response
meta-analysis to examine the potential nonlinear rela-
tionship between dietary magnesium intake and serum
magnesium concentration and the risk of hypertension.
Magnesium intake was modeled using restricted cubic
splines with four knots at the 5th, 35th, 65th and 95th
percentiles of the distribution [42, 43]. This method re-
quires the effect estimate with its variance estimate for
at least three known quantitative categories of exposure
with one category serving as the common referent
group. If a study did not report the distribution of mag-
nesium intake for individuals without hypertension, we
estimated the distribution using the method described
by Aune et al. (for detailed description, see Additional
file 1: Online supplement 1) [44]. For studies that did
not set the lowest exposure as reference, we used the
method described by Hamling et al. to make a trans-
formation (for detailed calculation, see Additional file 2:
Online supplement 2) [45]. The assigned dose of dietary
magnesium intake for each category was the midpoint
or median, and for the open categories half the width of
the adjacent category was used.
Subgroup analyses were conducted for duration of
follow-up, location, gender and adjustment for calcium,
sodium, potassium, fiber, exercise, cholesterol, saturated
fat intake and smoking. We also performed sensitivity
analyses by excluding different studies. The possibility of
publication bias was assessed by the combination of the
Egger’s test, the Begg’s test and visual inspection of fun-
nel plot [46].
Statistical software Stata (version 12.0, Stata Corp.,
College Station, TX) and Excel macro were used for all
analyses. All statistical tests were two-sided. A p-value <
0.05 was considered to be statistically significant, except
where otherwise specified.
Results
Description of the selected studies
By June 2016, 1,002 studies were retrieved, of which 973
were excluded after review of title or abstract (Fig. 1),
and 29 full-text articles were reviewed. We excluded fur-
ther ten studies that focused on special populations of:
pregnant women (six studies), children (one study), pa-
tients in the first year after renal transplantation (one
study), patients with an implantable cardioverter defib-
rillator (one study) and patients with anesthesia (one
study)). Additional two studies reporting the association
between urinary magnesium and hypertension risk were
also excluded. We further excluded three reviews and
six articles that did not provide risk estimates. Thus, the
meta-analysis included nine articles of ten independent
prospective cohort studies [25–33], with a total of
20,119 hypertension cases and 180,566 study partici-
pants. The characteristics of the studies included in the
analysis are summarized in Table 1. Among the ten co-
hort studies, eight were conducted in the USA [25–31],
one in Mexico [33] and one in Netherlands [32]. Both
male and female participants were recruited in six stud-
ies [28, 29, 31–33], whereas only males [26] or females
[25, 27, 30] were recruited in some studies. Dietary mag-
nesium intake was reported by seven studies [25–27, 29,
30, 33], while serum magnesium concentrations were ex-
amined in two studies [31, 32], and one study reported
both [28]. RRs and corresponding 95% CIs for every
magnesium category available from these studies were
presented in Additional files 3 and 4: Tables S1 and S2.
The range of dietary magnesium intake was 96–425 mg/
day and serum magnesium levels were 0.66–0.95 mmol/
L. The average score for quality of studies was 7 out of 9
in our assessment (Additional file 5: Table S3).
Dietary magnesium intake and risk of hypertension
Multivariable-adjusted relative risks for the highest vs.
lowest categories of individual studies and all studies
combined are shown in Fig. 2. The summary result indi-
cated a statistically significant inverse relationship be-
tween dietary magnesium intake and hypertension risk
(pooled RR = 0.92; 95% CI: 0.86, 0.98), and there was no
evidence of heterogeneity (I2 = 0; p = 0.48). The funnel
plot showed reasonable symmetry, with no evidence of
publication bias (Fig. 3, Egger’s test p = 0.95 and Begg’s
test p = 0.71). Figure 4 shows the individual and com-
bined RRs and corresponding 95% CIs for hypertension
risk of per 100 mg/day increment in dietary magnesium
Han et al. Nutrition Journal  (2017) 16:26 Page 3 of 12
intake (pooled RR = 0.95; 95% CI: 0.90, 1.00; I2 = 39.3%;
p = 0.13). The dose-response meta-analysis suggested a
marginal linear relationship between dietary magnesium
intake and hypertension risk (Fig. 5, p for linearity =
0.057), and we did not find evidence of a nonlinear rela-
tionship (Fig. 5, p for non-linearity = 0.21).
Serum magnesium concentration and risk of
hypertension
Four prospective cohort studies were included in the
analysis. There was no indication of publication bias
(Egger’s test p = 0.86 and Begg’s test p = 0.73). The
pooled RR is 0.91 (95% CI: 0.80, 1.02; p = 0.10) for the
highest vs. lowest categories (Fig. 6), which is marginally
significant, and no evidence of heterogeneity was ob-
served (I2 = 0; p = 0.48). The dose-response meta-analysis
demonstrated no association between the risk of hyper-
tension and per-unit increment of serum magnesium
concentration (p for linearity = 0.23). We did not find
the evidence of a nonlinear relationship between serum
magnesium concentration and risk of hypertension ei-
ther (p for non-linearity = 0.91). The results were hardly
changed in sensitivity analysis when different studies
were excluded.
Subgroup analysis
There was no statistically significant heterogeneity in the
effect of dietary magnesium intake on hypertension risk
in different populations. In the studies conducted in the
USA, the hypertension risk associated with lower dietary
magnesium intake tended to be lower, with duration of
follow-up more than 8 years and adjusting for calcium,
sodium, potassium, fiber, exercise, cholesterol, saturated
fat intake or smoking, (Table 2). The reduced hyperten-
sion risk associated with 100 mg/day was tended to be
observed when the duration of follow-up was more than
8 years and when the results were adjusted separately
for calcium, sodium, fiber, cholesterol, saturated fat in-
take or smoking (Table 2). Because of the limited data
availability, subgroup analysis was not conducted for
serum magnesium concentrations.
Discussion
Magnesium regulates the physical properties of cellular
membranes and their permeability, and could therefore
alter the permeability of cells for calcium and sodium,
which are important mechanisms in the development of
hypertension [47]. It has also been suggested that mag-
nesium acts as a calcium antagonist that modulates vas-
cular smooth muscle tone and contractibility by
affecting calcium ion concentrations, causing vasorelax-
ation [5]. Thus, magnesium deficiency might affect blood
pressure values, leading to hypertension, and supra-
nutritional magnesium intake might act as a mild antihy-
pertensive agent.
The present systematic review and meta-analysis of pro-
spective cohort studies demonstrated a statistically signifi-
cant inverse association between dietary magnesium
Fig. 1 Screening and selection of articles on dietary magnesium intake, serum magnesium concentration and risk of hypertension
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intake and the risk of hypertension. For a 100 mg/day in-
crease in dietary magnesium intake, the risk decreased by
5%. However, there was no significant association between
serum magnesium concentration and the risk of hyperten-
sion. The effect estimates show no heterogeneity among
studies included for both dietary magnesium intake and
serum magnesium concentration, which means that our
combination of former studies is relatively reliable.
Meanwhile, results indicated that other factors may be
associated with the findings in the studies, such as dur-
ation of follow-up and measures adjusted for, such as
calcium, sodium, potassium, fiber, exercise, cholesterol,
saturated fat intake and smoking, and the combination
of several ions supplementation [48]. In our meta-
analysis, subgroup analysis showed that after adjusting
separately for these factors, the inverse association pre-
sents a little lower than that without adjustment
(Table 2).
Dietary magnesium and blood pressure
For the past decades, a number of studies have exam-
ined the relationship between magnesium intake and
blood pressure. Four meta-analyses [21–24] and two sys-
tematic reviews have been conducted [49, 50], but re-
sults remained inconsistent. Mizushima et al. [50] found
a significantly negative association between dietary mag-
nesium intake and blood pressure, however, no quantita-
tive results were produced because of the difficulty in
combining estimates due to methodological differences
in dietary data collection, study design and potential
biases in studies involved. The present study effectively
avoided these problems and made a quantitative assess-
ment of the effect of dietary magnesium intake on
hypertension. On the other hand, Burgess et al. [49]
reviewed relevant epidemiologic studies and concluded
that higher dietary magnesium intake was not associated.
Of the four meta-analyses of randomized controlled tri-
als (RCTs) regarding the effect of magnesium supple-
mentation on the subsequent blood pressure, Jee et al.
reported a small and non-significant reduction in blood
pressure by analyzing 20 studies of hypertensive and
normotensive individuals. Dickinson et al. reported a
weak benefit of magnesium supplementation on blood
pressure. A meta-analysis in 2012 involving 22 RCTs
found a reduction of 3–4 mmHg SBP and 2–3 mmHg
Fig. 2 Forest plots of relative risks of hypertension for the highest versus lowest categories of dietary magnesium intake
Fig. 3 Funnel plot of studies reporting dietary magnesium intake
and the risk of hypertension
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DBP with oral magnesium supplementation. Notably, a
significant reduction of 18.7 mmHg in SBP and
10.9 mmHg in DBP was reported by Rosanoff et al., but
among a specific population of SBP > 155mmhg. For
normotensive individuals, studies showed that lower
dietary magnesium intake may correlate with elevated
blood pressure and thus with the development of hyper-
tension in general population [51, 52].
Serum magnesium and blood pressure
Studies reporting the association between serum magne-
sium and blood pressure were limited. Shibutani et al.
reported that Japanese children who had a hereditary
predisposition to hypertension tended to have higher
blood pressure and lower erythrocyte magnesium levels,
rather than serum magnesium [53]. Rinner et al. found
no relationship between serum magnesium and blood
pressure [54]. But Guerrero-Romero et al. conducted a
study using healthy Mexican children and found that
serum magnesium level <1.8 mg/dL was significantly as-
sociated with prehypertension and hypertension [55].
Compared with dietary magnesium, serum magnesium
may affect blood pressure more directly. Therefore, fur-
ther research is needed to examine the relationship be-
tween serum magnesium levels and blood pressure, the
incidence of hypertension and other cardiovascular
diseases.
Quality of included studies
The risk of bias in the studies included was low (Egger’s
test p = 0.95 and Begg’s test p = 0.71 for dietary magne-
sium intake and Egger’s test p = 0.86 and Begg’s test p =
0.73 for serum magnesium concentration), and studies
were generally considered of high quality (with relatively
high NOS scores). The degree of follow-up remained
limited, although in some studies only subgroups were
followed for longer duration. Differential loss to follow-
up between dose categories did not appear to be an
issue, and neither did selective publication. However,
eight of 10 studies included were from the USA, which
may have affected generalizability. Although difference
between the USA and non-USA reports indicated pos-
sible variations between different populations, evidence
from other regions has been limited, and further studies
are necessary to assess this issue.
Strengths and limitations
To the best of our knowledge, this is the first meta-
analysis focusing on prospective cohort studies to exam-
ine the association of dietary magnesium intake and
serum magnesium concentration with the risk of hyper-
tension with including the assessment of both linear and
nonlinear dose-response relationships.
A strength of our meta-analysis is the prospective fea-
ture of the studies included, which reduced risk of selec-
tion and recall biases that could be of concern in
Fig. 4 Forest plots of relative risks of hypertension for an increment of 100 mg/d of dietary magnesium intake
Fig. 5 Dose-response relationship between dietary magnesium
intake and risk of hypertension
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retrospective case-control studies. As a method for
quantifying nutrient intakes, FFQ was used in a case-
control study, while the reliability of FFQ may be low
even though the majority of FFQs have been validated
before application [56]. Cross-sectional studies suggested
no significant benefit of dietary magnesium intake on
hypertension risk in normotensive individuals, which
was different from our result [33, 57]. These studies,
however, used the 24-h dietary recall method to assess
magnesium exposure, which may be vulnerable to recall
and reporting biases, resulting in the misclassification of
dietary intake. A study assessed dietary magnesium in-
take with an FFQ only at baseline, but this may result in
underestimation the relative risk [58]. Furthermore,
most studies included in our study were adjusted for po-
tential confounders such as alcohol consumption, cal-
cium, sodium, potassium, fiber, physical activity,
cholesterol, saturated fat intake and smoking, removing
effect of these measures.
However, there are also limitations in our study. First,
residual confounding cannot be ruled out in observa-
tional studies. For example, only one study was adjusted
for calcium intake, which might affect the absorption of
magnesium [59]. In addition, unmeasured or unknown
factors might also be a source of confounding. Second,
the range of dietary magnesium levels is centered at ap-
proximately 150 mg/day to 400 mg/day that may weaken
the dose-response relationship at higher levels of magne-
sium intake. In Fig. 5, when the intake of dietary magne-
sium is beyond 370 mg/day, the insignificant result may
be caused by lack of statistical power. Third, there may
be specific subgroups that show different associations.
For example, Choi et al. reported obese women may
benefit more with increased magnesium intake [51]. In
our study, however, only a small number of studies were
included after applying the selection criteria and it was
not possible to assess associations in specific subgroups.
Four, the studies included did not report the effect of
supplemental magnesium on hypertension risk separ-
ately from other form of magnesium intakes. Thus, we
could not investigate the effect of supplemental magne-
sium specifically, but the use of supplemental magne-
sium was relatively minor compared with dietary
magnesium, as indicated by the study conducted by He
et al. that dietary magnesium intake was nearly compar-
able to total magnesium [29]. Finally, we only had four
studies reporting the serum magnesium concentration
and hypertension risk and failed to find any statistically
significant association with the risk of hypertension (RR
= 0.91; 95% CI: 0.80, 1.02).
Inferences
Magnesium is mainly consumed through diet, and low
magnesium consumption is common worldwide. It has
been estimated that magnesium intake in a normal
Western diet is often inadequate for the body’s needs; In
the Unit States, 56% of women and 53% of men con-
sume insufficient amounts of magnesium [60]. For
people aged more than 30, the recommended dietary al-
lowance of magnesium was 350 mg/day and 420 mg/day
for men and women, respectively [61]. On the basis of
the studies we have reviewed, current evidence from
population-based prospective cohort studies support the
recommendation for increasing the dietary magnesium
intake.
Implication for future research
More evidence is needed, especially on the dose-
response relationship between dietary magnesium intake
and hypertension in populations in Asia, Africa and Eur-
ope. Further research into biological mechanism and
how low magnesium intake could be reduced will help
developing evidence-based dietary recommendations
and interventions.
Conclusions
This meta-analysis including 10 prospective cohort stud-
ies found that magnesium intake showed a reduced risk
of incidence of hypertension with no evidence of hetero-
geneity. Our findings suggest that increased dietary
Fig. 6 Forest plots of relative risks of hypertension for the highest versus lowest categories of serum magnesium concentration
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Table 2 Pooled relative risk (RR) of hypertension and RR per 100 mg/d increment in dietary magnesium intake
Highest versus Lowest dietary magnesium intake Per 100 mg/day increment in dietary magnesium intake
Number of studies.a RR(95%CI) I2 (%) p for heterogeneity Number of studies. a RR(95%CI) I2 (%) p for heterogeneity
All studies 8 0.92(0.86,0.98) 0 0.48 7 0.95(0.90,1.00) 39.30 0.13
Location
USA 7 0.92(0.86,0.99) 5.40 0.39 7 0.95(0.90,1.00) 39.30 0.13
Other area 1 0.83(0.49,1.39) - - 0 - - -
Gender
Male 2 0.93(0.73,1.19) 0 0.70 2 0.81(0.64,1.03) 0 0.85
Female 4 0.94(0.82,1.07) 49.40 0.12 4 0.96(0.89,1.03) 62.60 0.05
Bothb 2 0.86(0.70,1.07) 0 0.87 1 0.96(0.88,1.06) - -
Follow-up (year)
≥ 8 2 0.90(0.83,0.98) 0 0.72 2 0.91(0.86,0.97) 4.40 0.31
< 8 6 0.94(0.83,1.07) 14.70 0.32 5 0.98(0.92,1.03) 23.90 0.26
Adjusted alcohol
Yes 6 0.92(0.84,1.00) 19.60 0.29 5 0.94(0.89,1.00) 53.00 0.07
No 2 0.98(0.76,1.27) 0 0.97 2 1.00(0.88,1.14) 0 0.41
Adjusted calcium
Yes 1 0.78(0.62,0.98) - - 1 0.90(0.82,0.99) - -
No 7 0.94(0.87,1.00) 0 0.64 6 0.96(0.91,1.02) 40.50 0.14
Adjusted sodium
Yes 2 0.91(0.83,0.99) 0 0.73 1 0.92(0.87,0.97) - -
No 6 0.93(0.83,1.05) 18.30 0.30 6 0.96(0.90,1.03) 34.10 0.18
Adjusted potassium
Yes 2 0.81(0.67,0.98) 0 0.52 2 0.93(0.86,1.00) 0 0.32
No 6 0.94(0.87,1.01) 0 0.52 5 0.96(0.89,1.03) 52.20 0.08
Adjusted fiber
Yes 3 0.84(0.72,0.97) 0 0.74 3 0.92(0.85,0.99) 6.20 0.35
No 5 0.94(0.88,1.02) 0 0.44 4 0.97(0.91,1.05) 53.30 0.09
Adjusted diabetes
Yes 2 0.91(0.84,1.00) 0 0.66 2 0.96(0.85,1.09) 50.60 0.16
No 6 0.92(0.82,1.04) 19.80 0.28 5 0.95(0.89,1.02) 40.40 0.15
Adjusted family history of hypertension
Yes 2 0.93(0.69,1.26) 0 0.59 1 1.06(0.88,1.28) - -
No 6 0.92(0.84,1.01) 19.30 0.29 6 0.94(0.90,1.00) 41.30 0.13
Adjusted education
Yes 2 0.90(0.74,1.10) 0 0.56 2 0.94(0.72,1.22) 67.00 0.08
No 6 0.93(0.84,1.02) 18.20 0.30 5 0.95(0.90,1.00) 41.50 0.15
Adjusted exercise
Yes 4 0.91(0.84,0.98) 0 0.93 3 0.93(0.84,1.03) 38.70 0.20
No 4 0.94(0.78,1.12) 45.90 0.14 4 0.97(0.91,1.03) 33.50 0.21
Adjusted cholesterol
Yes 3 0.90(0.83,0.98) 0 0.89 2 0.91(0.86,0.97) 4.40 0.31
No 5 0.95(0.82,1.10) 28.30 0.23 5 0.98(0.92,1.03) 23.90 0.26
Adjusted saturated fat intake
Yes 3 0.90(0.83,0.98) 0 0.89 2 0.91(0.86,0.97) 4.40 0.31
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magnesium intake was associated with lower risk of
hypertension in a linear dose-response pattern. Magne-
sium consumption have often found inadequate and low
among adult population worldwide, and our results sup-
port the recommendation for increasing the dietary
magnesium intake. However, no statistically significant
association was found between serum magnesium con-
centration and risk of hypertension. The data for the
high level of dietary magnesium intake were sparse, and
further research including randomized clinical trials is
needed to examine the effects of dietary magnesium in-
take on hypertension at high doses.
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